The H 2 S‐releasing metformin hybrid Met‐ITC protects against diabetes‐associated vascular dysfunction preserving glycaemic control
Das H2S-freisetzende Metformin-Hybrid Met-ITC schützt vor diabetesassoziierter Gefäßdysfunktion unter Erhalt der glykämischen Kontrolle
British Journal of Pharmacology · 2026-11-05
DOI: 10.1111/bph.70723 ↗Auf einen Blick
Met-ITC erhielt in präklinischen Modellen die antidiabetische Wirkung von Metformin und zeigte zugleich vaskuläre Schutzwirkungen. Unter anderem wurde eine bessere Schutzwirkung gegen oxidativen Stress und Seneszenz beschrieben.
Fragestellung
Erhält das H2S-freisetzende Metformin-Hybrid Met-ITC die antidiabetische Wirkung von Metformin und schützt zusätzlich Gefäße bei diabetesassoziierter Dysfunktion?
Methode
Präklinische Studie: ADME-Analyse in silico, Glukoseaufnahme in HepG2-Zellen, oraler Glukosetoleranztest in db/db-Mäusen sowie Versuche an humanen Endothel- und glatten Gefäßmuskelzellen und an Rattenaortenringen.
Ergebnisse
Met-ITC zeigte ein günstigeres Permeabilitätsprofil als Metformin und behielt das antidiabetische Profil bei. Es schützte besser vor oxidativem Stress, Verlust der Zellviabilität und Seneszenz und induzierte Vasodilatation in Rattenaortenringen.
Schlussfolgerung der Autor:innen
Die Befunde identifizieren Met-ITC als potenziellen Kandidaten zur Behandlung diabetesassoziierter Gefäßdysfunktion.
Kernaussagen
- Antidiabetisches Profil von Metformin blieb unter Met-ITC erhalten
- Bessere Schutzwirkung gegen oxidativen Stress, Zellverlust und Seneszenz
- Vasodilatation in Rattenaortenringen und Hemmung noradrenalininduzierter Konstriktion
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
At a glance
Journal article in British Journal of Pharmacology, published online on 2026-11-05. Written by Jacopo Spezzini and 10 co-authors. Institution: Department of Pharmacy, University of Pisa, Pisa, Italy. 65 references. Funded by: Italian Ministry of University and Research (MIUR), "SPARK PISA" University of Pisa/University of Stanford.
Topics: Diabetes mellitus
Abstract (original language)
Background and Purpose Patients undergoing metformin (Met) therapy for the treatment of type 2 diabetes remain at high cardiovascular risk. Hydrogen sulphide (H 2 S)‐releasing molecules offer antioxidant, anti‐senescence and vasoactive properties that may complement Met activity. This study investigated whether metformin–isothiocyanate (Met‐ITC), a H 2 S‐releasing metformin hybrid, preserves the antidiabetic activity of Met while providing H 2 S‐derived vascular protection. Experimental Approach The predicted Absorption, Distribution, Metabolism and Excretion (ADME) properties of Met and Met‐ITC were evaluated in silico. Maintenance of Met antidiabetic properties was assessed in vitro by evaluating glucose uptake in HepG2 cells and in vivo through oral glucose tolerance tests in db/db mice. The ability of Met‐ITC to release H 2 S and its ability to preserve cell viability and contrast ROS formation and cellular senescence were evaluated in human aortic endothelial cells (HAECs) and smooth muscle cells (HASMCs) exposed to hydrogen peroxide, homocysteine or high‐glucose concentrations. The hyperpolarizing effect of Met‐ITC was tested on HASMCs and its direct vasorelaxing effect as well as its ability to inhibit noradrenaline‐induced vasoconstriction were tested on endothelium‐intact or ‐denuded rat aortic rings. Key Results Met‐ITC showed a more favourable permeability profile than Met and maintained its antidiabetic profile. It provided better protection against oxidative stress, loss of cell viability and senescence compared with Met. Moreover, Met‐ITC produced a concentration‐dependent hyperpolarization of HASMCs, restricted noradrenaline‐induced contraction and induced vasodilatation in endothelium‐denuded and ‐intact rat aortic rings. Conclusion and Implications These findings identify Met‐ITC as a potential candidate for the treatment of diabetes‐associated vascular dysfunction.
Subjects
Author keywords
Authors and institutions
- Department of Pharmacy, University of Pisa, Pisa, Italy.
- Interdepartmental Research Center "Biology and Pathology of Ageing", University of Pisa, Pisa, Italy.
- Center for Instrument Sharing of the University of Pisa (CISUP), University of Pisa, Pisa, Italy.
ORCID profiles: Jacopo Spezzini, Eugenia Piragine, Lorenzo Flori, Valentina Citi, Simone Brogi, Lara Testai, Elisabetta Barresi, Sabrina Taliani, Federico Da Settimo, Vincenzo Calderone, Alma Martelli
Funding
- Italian Ministry of University and Research (MIUR)
- "SPARK PISA" University of Pisa/University of Stanford
Cite
APA
Spezzini, J., Piragine, E., Flori, L., Citi, V., Brogi, S., Testai, L., Barresi, E., Taliani, S., Da Settimo, F., Calderone, V., & Martelli, A. (2026). The H 2 S‐releasing metformin hybrid Met‐ITC protects against diabetes‐associated vascular dysfunction preserving glycaemic control. British Journal of Pharmacology. https://doi.org/10.1111/bph.70723
Vancouver
Spezzini J, Piragine E, Flori L, Citi V, Brogi S, Testai L, et al. The H 2 S‐releasing metformin hybrid Met‐ITC protects against diabetes‐associated vascular dysfunction preserving glycaemic control. British Journal of Pharmacology. 2026. doi:10.1111/bph.70723
BibTeX
@article{Spezzini2026,
author = {Spezzini, Jacopo and Piragine, Eugenia and Flori, Lorenzo and Citi, Valentina and Brogi, Simone and Testai, Lara and Barresi, Elisabetta and Taliani, Sabrina and Da Settimo, Federico and Calderone, Vincenzo and Martelli, Alma},
title = {The H 2 S‐releasing metformin hybrid Met‐ITC protects against diabetes‐associated vascular dysfunction preserving glycaemic control},
journal = {British Journal of Pharmacology},
year = {2026},
doi = {10.1111/bph.70723}
}
EUVIMED